AI summary
Summary of article:
Moderna and Merck’s optimized mRNA melanoma vaccine reduced the risk of recurrence or death by 42% in a phase 3 trial and shows potential for application approval.
pharmaceutical factorymodena (Moderna) and Merck (Merck) a successful messenger ribonucleic acid (mRNA) cancervaccine Which reduced the risk of melanoma recurrence or death by 42% in phase 3 clinical trials.
Washington Post According to reports, the “Intismeron Autogene” drug is customized according to the genetic characteristics of each patient’s tumor, uses the same mRNA platform as the new coronavirus (Covid) vaccine, and is used in combination with existing immunotherapy drugs to improve efficacy.
Compared with standard treatments, Intisemeran Autogene can reduce the risk of melanoma recurrence or death by up to 42% and reduce the risk of cancer cells spreading to other parts of the body or dying by about 38%.
Overall survival data, which typically takes longer to evaluate, is inconclusive, but researchers have seen “favorable trends.” Side effects of the new drug were consistent with previous studies, including fatigue, chills and pain at the injection site.
“It feels very positive,” said Karen Knudsen, CEO of the Parker Institute, a nonprofit organization focused on developing cancer treatments.
“These results strengthen our belief that mRNA has the potential to fundamentally change the way cancer is treated,” Moderna CEO Stéphane Bancel said in a statement.
This complete data was originally scheduled to be announced at the annual meeting of the European Society for Medical Oncology (ESMO) in Madrid, Spain on the 24th, but this news was accidentally leaked on the 22nd.
Consumer News & Business Channel (CNBC) reported that the intisemeran autogene experimental data had already been revealed, causing Moderna’s share price to fall nearly 25% that day; Some analysts believe that market expectations are too high, rather than a problem with the data.
Janice. Janice Mehnert described it as “first-class technology”.
Melanoma is the deadliest form of skin cancer. The National Cancer Institute estimates there will be more than 100,000 new cases of melanoma this year. Tumors often recur after they have been removed and this vaccine is suitable for people who have had their tumors removed.
Moderna and Merck said they are in contact with regulatory authorities and expect to apply for approval from the federal Food and Drug Administration (FDA) “as soon as possible.”
Summary FAQ
-
Phase III clinical trials show that intisemeran autogene can reduce the risk of melanoma recurrence or death by up to 42%, and reduce the risk of cancer cells spreading to other parts or causing death by about 38%. The effect is much better than standard treatment.
-
This vaccine will be customized according to the genetic characteristics of each patient’s tumor, using the same mRNA platform as the Covid vaccine, and will be used in combination with existing immunotherapy drugs to improve the overall treatment effect.
-
The researchers reported that side effects were consistent with previous results, which primarily included fatigue, chills, and pain at the injection site; Moderna’s share price fell nearly 25% due to the early presentation of the data, and the company is in contact with regulatory authorities and expects to apply for approval from the FDA as soon as possible.
